Human CD19 targeted T Cells Injection

DRUG2 trials

Sponsors

Hrain Biotechnology Co., Ltd.

Conditions

Acute Lymphoblastic LeukemiaCD19-positiveDiffuse Large B-cell LymphomaFollicular Lymphoma

Phase 1

Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma.

Hrain Biotechnology Co., Ltd.CD19-positive, Diffuse Large B-cell Lymphoma, Follicular Lymphoma

Start: 2018-11-13End: 2023-10-31Target: 18Updated: 2021-08-31

Human CD19 Targeted T Cells Injection Therapy for Relapsed and Refractory CD19-positive Leukemia

Hrain Biotechnology Co., Ltd.Acute Lymphoblastic Leukemia, CD19-positive

Start: 2019-03-13End: 2024-01-31Target: 18Updated: 2021-08-31

Related Papers

A simple and effective method to purify and activate T cells for successful generation of chimeric antigen receptor T (CAR-T) cells from patients with high monocyte count

Journal of Translational Medicine2022-12-1919 citations